These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38179696)

  • 21. Effectiveness and safety of hFVIII/VWF concentrate (Voncento
    Rugeri L; d'Oiron R; Harroche A; Proulle V; Mourey G; De Raucourt E; Desprez D; Baikian NI; Petesch BP; Borel-Derlon A; Combe S; Frotscher B; Hassoun A; Catovic H; Bracquart D; Trossaërt M
    Blood Transfus; 2021 Mar; 19(2):152-157. PubMed ID: 33263522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease.
    Ver Elst KM; van Vliet HD; Kappers-Klunne MC; Leebeek FW
    Thromb Haemost; 2004 Jul; 92(1):67-74. PubMed ID: 15213847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.
    Viswabandya A; Mathews V; George B; Nair SC; Baidya S; Mammen JJ; Chandy M; Srivastava A
    Haemophilia; 2008 Jul; 14(4):763-7. PubMed ID: 18445014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery.
    Di Paola J; Lethagen S; Gill J; Mannucci P; Manco-Johnson M; Bernstein J; Nichols WL; Bergman GE
    Haemophilia; 2011 Sep; 17(5):752-8. PubMed ID: 21689209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haemostatic management of intraoral bleeding in patients with von Willebrand disease.
    Morimoto Y; Yoshioka A; Sugimoto M; Imai Y; Kirita T
    Oral Dis; 2005 Jul; 11(4):243-8. PubMed ID: 15984956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgical prophylaxis in von Willebrand's disease: a difficult balance to manage.
    Franchini M
    Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s33-8. PubMed ID: 19105508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
    Dunkley S; Baker RI; Pidcock M; Price J; Seldon M; Smith M; Street A; Maher D; Barrese G; Stone C; Lloyd J
    Haemophilia; 2010 Jul; 16(4):615-24. PubMed ID: 20331755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diagnosis and management of von Willebrand disease].
    Higasa S; Tokugawa T; Sawada A
    Rinsho Ketsueki; 2018; 59(10):2222-2232. PubMed ID: 30305529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.
    Rivard GE; Aledort L;
    Haemophilia; 2008 Mar; 14(2):271-5. PubMed ID: 18194310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.
    Mannucci PM; Chediak J; Hanna W; Byrnes J; Ledford M; Ewenstein BM; Retzios AD; Kapelan BA; Schwartz RS; Kessler C;
    Blood; 2002 Jan; 99(2):450-6. PubMed ID: 11781224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB
    Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.
    Shortt J; Dunkley S; Rickard K; Baker R; Street A
    Haemophilia; 2007 Mar; 13(2):144-8. PubMed ID: 17286766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy.
    Gill JC; Ewenstein BM; Thompson AR; Mueller-Velten G; Schwartz BA;
    Haemophilia; 2003 Nov; 9(6):688-95. PubMed ID: 14750934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of a VWF/FVIII concentrate (wilate
    Srivastava A; Serban M; Werner S; Schwartz BA; Kessler CM;
    Haemophilia; 2017 Mar; 23(2):264-272. PubMed ID: 28026130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.